Summit Therapeutics Inc. (SMMT) Key Metrics
SMMT key metrics, 2016–2025
Fiscal year ended December 31, 2025 · British poundsSMMT returns How much profit the business earns on the capital it uses.
SMMT financial health Debt, liquidity and how easily interest is covered.
SMMT efficiency & capital use Working capital cycle and where the cash goes.
SMMT returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
SMMT debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
SMMT key metrics in British pounds
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −270.0% | −95.0% | −585.6% | −79.0% | −143.5% | −64.5% | 8.5% | 31.2% | −419.4% | — |
| Return on invested capital (ROIC) | — | — | — | −37.3% | −664.3% | −520.0% | 93.5% | 44.7% | — | — |
| Return on assets (ROA) | −238.4% | −69.5% | −137.4% | −20.8% | −108.1% | −51.1% | 6.4% | 13.9% | −32.7% | −51.7% |
| Return on tangible assets | −194.2% | −51.0% | −303.2% | −12.3% | −115.1% | −59.0% | 7.5% | 17.2% | −38.8% | −51.1% |
| Free cash flow margin | — | — | — | — | — | — | −36.8% | −61.8% | −150.0% | 634.1% |
| Income quality (OCF / net income) | — | — | — | — | — | — | −5.34 | −3.23 | — | — |
| Financial health | ||||||||||
| Total debt | £15.5M | £5.8M | £84.0M | £422.9M | £2.1M | £341,545 | £699,638 | £0 | £18.0M | £5.1M |
| Cash & short-term investments | £529.5M | £329.5M | £147.4M | £284.2M | £53.2M | £48.8M | £50.0M | £35.2M | £28.5M | £35.1M |
| Net debt | −£514.0M | −£323.7M | −£63.4M | £138.7M | −£51.2M | −£48.4M | −£49.3M | −£35.2M | −£10.4M | −£30.0M |
| Debt / equity | 0.03 | 0.02 | 1.37 | 4.10 | 0.03 | 0.01 | 0.01 | 0.00 | 1.29 | — |
| Debt / assets | 0.03 | 0.02 | 0.52 | 0.78 | 0.02 | 0.00 | 0.01 | 0.00 | 0.24 | 0.11 |
| Net debt / EBITDA | — | — | — | — | — | — | −3.14 | −3.02 | — | — |
| Current ratio | 9.87 | 10.15 | 9.30 | 16.93 | 3.80 | 4.41 | 6.27 | 3.56 | 1.89 | 3.06 |
| Quick ratio | 9.87 | 10.15 | 9.15 | 16.71 | 3.42 | 5.21 | 6.27 | 3.56 | 1.89 | 3.05 |
| Interest coverage | — | -20.8 | -29.1 | -13.5 | -306.7 | -281.0 | 363.0 | 8.7 | -15.7 | -23.1 |
| Working capital | £480.4M | £305.3M | £134.0M | £503.7M | £53.1M | £49.8M | £52.2M | £44.0M | £24.0M | £28.1M |
| Invested capital | −£25.0M | −£13.1M | −£1.9M | £242.0M | £10.6M | £9.9M | £11.9M | £20.6M | £3.6M | −£34.3M |
| Tangible asset value | £487.5M | £309.2M | £60.0M | £91.4M | £52.5M | £48.4M | £52.2M | £39.5M | −£10.5M | −£9.5M |
| Net current asset value | £466.1M | £301.2M | £51.0M | £97.2M | £49.8M | £47.5M | £47.8M | £37.5M | −£11.6M | −£9.7M |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | — | — | £0 | £0 | £0 |
| Share buybacks (net) | — | — | — | — | — | — | — | £0 | £0 | £0 |
| Dividend payout ratio | — | — | — | — | — | — | — | 0.0% | — | — |
| Dividends + buybacks / free cash flow | — | — | — | — | — | — | — | — | — | 0.0% |
| Capex / revenue | — | — | — | 87.2% | 12.5% | 49.2% | 0.6% | 0.3% | 4.8% | 4.6% |
| Capex / operating cash flow | — | — | — | — | — | — | — | — | — | 0.7% |
| Capex / depreciation | 3.34 | 1.25 | 0.51 | 0.40 | 0.09 | 0.15 | 0.19 | 0.08 | 1.20 | 1.87 |
| Stock-based compensation / revenue | — | — | — | 1,670.1% | 524.7% | 206.3% | 1.3% | 11.0% | 16.1% | 72.5% |
| R&D / revenue | — | — | — | 7,375.7% | 4,718.2% | 6,194.7% | 91.1% | 86.0% | 204.5% | 797.6% |
| SG&A / revenue | — | — | — | 3,793.3% | 1,305.2% | 2,236.3% | 21.6% | 28.4% | 84.2% | 348.4% |
| Efficiency | ||||||||||
| Days sales outstanding | — | — | — | 5,540.3 | 2,038.1 | 2,263.7 | 54.4 | 82.0 | 230.4 | 539.1 |
| Days of inventory on hand | — | — | 854.8 | 1,039.7 | — | — | 0.0 | — | — | 1,994.2 |
| Days payables outstanding | 31,604.6 | 70.7 | 213.7 | 256.4 | — | — | 8,393.1 | 135,069.2 | 32,929.8 | 28,257.6 |
| Cash conversion cycle (days) | — | — | — | 6,323.6 | — | — | -8,338.7 | -134,987.2 | -32,492.8 | -25,724.3 |
| Receivables turnover | — | 0.00 | 0.00 | 0.07 | 0.18 | 0.16 | 6.71 | 4.45 | 1.58 | 0.68 |
| Payables turnover | 0.01 | 5.16 | 1.71 | 1.42 | 0.00 | 0.00 | 0.04 | 0.00 | 0.01 | 0.01 |
| Inventory turnover | — | — | 0.43 | 0.35 | — | — | 255,766.67 | — | — | 0.18 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.01 | 0.56 | 0.73 | 0.23 | 0.06 |
| Average receivables | — | £558,080 | £2.8M | £8.9M | £10.1M | £3.9M | £6.4M | £12.8M | £8.9M | £3.5M |
| Average payables | £9.4M | £2.9M | £1.2M | £1.8M | £3.9M | £3.9M | £4.6M | £9.2M | £8.8M | £4.8M |
| Average inventory | — | — | £4.8M | £7.2M | −£2.3M | −£5.9M | £1 | £0 | £55,278 | £336,829 |
| Intangibles / total assets | 0.3% | 0.4% | 0.9% | 2.2% | 10.9% | 13.2% | 11.8% | 20.5% | 32.0% | 11.0% |
Computed from SMMT's annual financial statements (latest annual report filed February 23, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in British pounds; data from EODHD. Averages use the opening and closing balance of each year.
SMMT valuation and financial ratios
Summit Therapeutics earned a return on equity of −270.0% in fiscal 2025. It ended the year with £15.5 million of debt and £529.5 million in cash and short-term investments, a net cash position of £514.0 million.
See the SMMT income statement, the SMMT chart for price history, or the SMMT stock overview for the latest quote and news.
SMMT key metrics FAQ
What is Summit Therapeutics's return on equity?
Summit Therapeutics's return on equity (ROE) was −270.0% in fiscal 2025: net income of -£1.1 billion on average shareholders' equity of £399.8 million.
How much debt does Summit Therapeutics have?
Summit Therapeutics had total debt of £15.5 million at the end of fiscal 2025, a debt-to-equity ratio of 0.03 and more cash than debt.
What is Summit Therapeutics's current ratio?
Summit Therapeutics's current ratio was 9.87 at the end of fiscal 2025: current assets were 9.87 times current liabilities.